PDE Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “PDE Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in PDE Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
PDE Inhibitors: Overview
Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis. Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects. Hypersensitivity is an absolute contraindication to all phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may result in severe hypotension. Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before phosphodiesterase inhibitor use.
'PDE Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the PDE Inhibitors pipeline landscape is provided which includes the disease overview and PDE Inhibitors treatment guidelines. The assessment part of the report embraces, in depth PDE Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, PDE Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the PDE Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PDE Inhibitors Emerging Drugs
Further product details are provided in the report……..
PDE Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PDE Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
PDE Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PDE Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PDE Inhibitors drugs.
PDE Inhibitors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “PDE Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in PDE Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
PDE Inhibitors: Overview
Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis. Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects. Hypersensitivity is an absolute contraindication to all phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may result in severe hypotension. Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before phosphodiesterase inhibitor use.
'PDE Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the PDE Inhibitors pipeline landscape is provided which includes the disease overview and PDE Inhibitors treatment guidelines. The assessment part of the report embraces, in depth PDE Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, PDE Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence PDE Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve PDE Inhibitors.
This segment of the PDE Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PDE Inhibitors Emerging Drugs
- ARQ-151: Arcutis Biotherapeutics
- Ensifentrine: Verona Pharma
Further product details are provided in the report……..
PDE Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PDE Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in PDE Inhibitors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
PDE Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PDE Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PDE Inhibitors drugs.
PDE Inhibitors Report Insights
- PDE Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing PDE Inhibitors drugs?
- How many PDE Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PDE Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PDE Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for PDE Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arcutis Biotherapeutics
- Chiesi Farmaceutici
- Imara Inc
- Verona Pharma
- Eisai Inc
- vTv Therapeutics
- Tetra Therapeutics
- Palobiofarma
- ARQ-151
- CHF-6001
- IMR-687
- Ensifentrine
- E 2027
- HPP-737
- BPN-14770
- BTX-2640
- PBF-999
Introduction
Executive Summary
PDE Inhibitors: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Ensifentrine: Verona Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
IMR-687: Imara Inc
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
BTX-2640: BioTheryX
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
PDE Inhibitors Key Companies
PDE Inhibitors Key Products
PDE Inhibitors- Unmet Needs
PDE Inhibitors- Market Drivers and Barriers
PDE Inhibitors Key Companies
Appendix
Executive Summary
PDE Inhibitors: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Ensifentrine: Verona Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
IMR-687: Imara Inc
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
BTX-2640: BioTheryX
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
PDE Inhibitors Key Companies
PDE Inhibitors Key Products
PDE Inhibitors- Unmet Needs
PDE Inhibitors- Market Drivers and Barriers
PDE Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for PDE Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for PDE Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for PDE Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for PDE Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
